We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+18.97%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$26.5B
AUM Growth
+$1.52B
Cap. Flow
-$117M
Cap. Flow %
-0.44%
Top 10 Hldgs %
84.24%
Holding
133
New
14
Increased
16
Reduced
60
Closed
7

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$478M
2
NVTA
Invitae Corporation
NVTA
+$181M
3
KOD icon
Kodiak Sciences
KOD
+$170M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$52.7M
5
OPT
Opthea Limited American Depositary Shares
OPT
+$41.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$450M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$410M
3
EXAS
Exact Sciences
EXAS
+$188M
4
IMMU
Immunomedics Inc
IMMU
+$20.2M
5
AMRN
Amarin Corp
AMRN
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGM
101
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$3.23M 0.01%
106,616
-11,484
-10% -$251K
CHMA
102
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.23M 0.01%
742,133
– –
AKRO
103
DELISTED
Akero Therapeutics
AKRO
$3.05M 0.01%
118,378
-13,410
-10% -$373K
XLRN
104
DELISTED
Acceleron Pharma
XLRN
$2.87M 0.01%
22,430
-3,210
-13% -$376K
DRNA
105
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.25M 0.01%
102,121
-11,014
-10% -$243K
INZY
106
DELISTED
Inozyme Pharma
INZY
$2.21M 0.01%
106,999
-11,501
-10% -$274K
OVID icon
107
Ovid Therapeutics
OVID
$547M
$2.21M 0.01%
955,690
+364,929
+62% +$1.7M
VKTX icon
108
Viking Therapeutics
VKTX
$3.95B
$2.05M 0.01%
363,980
-40,220
-10% -$244K
RCUS icon
109
Arcus Biosciences
RCUS
$3.86B
$1.89M 0.01%
72,709
-42,716
-37% -$1.03M
ORTX
110
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.44M 0.01%
33,250
-1,070
-3% -$47.9K
CYPH
111
Cypherpunk Technologies Inc
CYPH
$153M
$1.26M ﹤0.01%
55,971
– –
MTEM
112
DELISTED
Molecular Templates, Inc.
MTEM
$1.26M ﹤0.01%
8,922
-999
-10% -$148K
OYST
113
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$1.16M ﹤0.01%
61,424
-6,804
-10% -$147K
LKFT
114
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$1.11M ﹤0.01%
11,180
-1,232
-10% -$151K
INFI
115
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.11M ﹤0.01%
522,360
-58,040
-10% -$95.7K
EVFM
116
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$991K ﹤0.01%
27,426
-1,444
-5% -$52.2K
AFMD
117
DELISTED
Affimed
AFMD
$958K ﹤0.01%
16,461
-2,519
-13% -$119K
BLCM
118
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$879K ﹤0.01%
249,123
– –
KZR
119
DELISTED
Kezar Life Sciences
KZR
$729K ﹤0.01%
13,968
-43,528
-76% -$2.42M
ADMS
120
DELISTED
Adamas Pharmaceuticals
ADMS
$641K ﹤0.01%
147,996
-15,834
-10% -$67.8K
GLMD icon
121
Galmed Pharmaceuticals
GLMD
$4.48M
$575K ﹤0.01%
128
-15
-10% -$74.9K
QURE icon
122
uniQure
QURE
$3.36B
$244K ﹤0.01%
6,740
-187,643
-97% -$7.92M
VIRX
123
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$106K ﹤0.01%
15,162
– –
GNFT
124
DELISTED
Genfit
GNFT
$71K ﹤0.01%
14,720
-13,676
-48% -$64.3K
APLT
125
DELISTED
Applied Therapeutics
APLT
– –
-38,034
Closed -$790K
2 3 4
5
6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2020 Portfolio in Review

As of Q4 2020, Julian Baker held 133 positions worth $26.5B, up 6.1% from $25B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Julian Baker's Q4 2020 filing shows 14 new, 16 increased, 60 reduced and 7 closed positions. Its largest new stake was AbCellera Biologics: 10,450,180 shares worth $421M. The largest sale was BeOne Medicines Ltd, an estimated $450M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q4 2020 buy was AbCellera Biologics: 10,450,180 shares worth $421M.
  • Julian Baker added most to Invitae Corporation in Q4 2020, an estimated $181M increase.
  • Julian Baker's biggest Q4 2020 reduction was BeOne Medicines Ltd, cutting an estimated $450M.
  • Julian Baker fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $410M.
  • Julian Baker's ten largest holdings make up 84% of its $26.5B portfolio in Q4 2020.
  • Julian Baker opened 14 new positions and closed 7 in Q4 2020.
  • Julian Baker's portfolio value rose 6.1% quarter-over-quarter to $26.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.